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The coexistence of heart failure and renal dysfunction constitutes the “cardiorenal syndrome” which is increasingly recognized as
a marker of poor prognosis. Patients with cardiorenal dysfunction constitute a large and heterogeneous group where individuals
can havemarkedly diﬀerent outcomesanddisease courses. Thus, thedetermination of prognosisin this high riskgroup of patients
may pose challenges for cliniciansand for researchers alike. In this paper, we discuss the cardiorenal syndrome as it pertains to the
patient with heart failure and considerations for further reﬁning prognosis and outcomes in patients with heart failure and renal
dysfunction. Conventional assessments of left ventricular function, renal clearance, and functional status can be complemented
with identiﬁcation of coexistent comorbidities, medication needs, microalbuminuria, anemia, biomarker levels, and pulmonary
pressures to derive additional prognostic data that can aid managementand provide future research directions forthis challenging
patient group.
1.Introduction:TheScopeofthe
CardiorenalSyndrome
Cardiac and renal dysfunctions often coexist. Approximately
70% of patients from community-based studies of heart
failure (HF) have renal impairment, and 29% have moderate
to severe renal dysfunction [1]. Furthermore, a published
series from the Mayo Clinic reported that the serum
creatinine levels of HF patients have increased steadily from
1987 to 2002 [2]. An analysis of the Candesartan in Heart
Failure:Assessment ofReductioninMortalityand Morbidity
(CHARM) trials demonstrated that the prevalence of renal
dysfunction was similar among patients with preserved
ejection fraction and those with systolic dysfunction [3].
Moreover, a comparison of patients with ischemic HF
and idiopathic dilated cardiomyopathy revealed that renal
dysfunction was common in both patient groups [4]. This
suggests that renal dysfunction in HF does not simply
reﬂect the degree of left ventricular dysfunction or systemic
atherosclerosis. While a universal, simple deﬁnition of the
cardiorenal syndrome (CRS) remains elusive, a classiﬁcation
scheme based on the underlying precipitant of the CRS has
been proposed [5]( s e eTable 1).
Renal function is one of the strongest prognostic factors
among patients with HF.In a meta-analysis of approximately
78,000 patients with HF, Smith et al. [1] showed that renal
impairment portended an increased risk of death, with
an adjusted hazard ratio (HR) of 1.56 (95% CI: 1.53–
1.60, P<. 001). Hillege et al. [3]d e m o n s t r a t e dt h a t
t h i sr i s kw a so b s e r v e da c r o s st h er a n g eo fe G F R sb e l o w
60mL/min/1.73m2. The negative prognosis associated with
a 10mL/min/1.73m2 decline in eGFR was comparable to
that of a 5% decline in left ventricular ejection fraction
(LVEF). Moreover, the prognostic value of eGFR was not
signiﬁcantly diﬀerent among patients with reduced or pre-
served left ventricular ejection fraction. However, it has been2 International Journal of Nephrology
Table 1: Classiﬁcation scheme of the diﬀerent types of the cardiorenal syndrome.
Type Name Description
1 Acute CRS Acute worseningof heart function leading to kidney injury and/or dysfunction
2 Chronic CRS Chronic abnormalities in heart function leading to kidney injury and/or dysfunction
3 Acute renocardiac syndrome Acute worsening of kidney function leading to heart injury and/or dysfunction
4 Chronic renocardiac syndrome Chronic kidney disease leading to heart injury, disease, and/or dysfunction
5 Secondary CRS Systemic conditions leading to simultaneous injury and/or dysfunction of heart and kidney
suggested that renal dysfunction might be associated with
worse outcomes in patients with idiopathic cardiomyopathy,
compared to those with an ischemic HF etiology [4].
Accordingly, patients with combined cardiac and renal
dysfunction constitute a high risk group that is also large
and heterogeneous, supporting the need for additional
parameters to further delineate their risk of death and/or
disease progression. The strongest prognostic information
for these patients will continue to be derived from LVEF,
estimates of renal function and New York Heart Association
(NYHA) functional status. However, other clinical variables
may play an increasingly important role in risk stratifying
this large patient group with the ultimate aim of targeted
interventions to improve outcomes.
2.MeasurementofRenalDysfunction in
HeartFailure
Renal function can be estimated in several ways, yield-
ing diﬀerent estimates of eGFR. This becomes especially
prominent among CHF patients whose body compositions
might be markedly diﬀerent than the chronic kidney disease
(CKD) populations in whom these formulas were derived.
Smilde et al. prospectively validated the accuracy and
prognostic value of the Cockcroft-Gault (CG), Modiﬁcation
of Diet in Renal Disease (MDRD), and simpliﬁed MDRD
(sMDRD) equations among patients with HF by compar-
ison with the gold standard of 125I-iothalamate clearance
[6]. All three formulas overestimated GFR in the lower
ranges (<35mL/min/1.73m2), underestimated it in the
upper ranges (>65mL/min/1.73m2), and functioned best in
patients with NYHA classes III and IV. The MDRD was the
most precise formula, while the CG was marginally more
accurate. In comparison with directly measured GFR, the
bestprognosticvalueforcardiovascularoutcomescamefrom
creatinine clearancemeasurements using24-hour urines and
the MDRD equation, while the CG equation provided the
least prognostic value. It has been reported that serum urea
levels can also provide valuable prognostic information in
CRS [7].
Accordingly,24-hour urine collections should be period-
ically considered for determination of creatinine and urea
clearance in HF patients with eGFR <35mL/min/1.73m2,
especially if heart transplantation or renal replacement ther-
apy are being considered. Since creatinine is actively excreted
into urine while urea is actively reabsorbed, measured
creatinine clearance can signiﬁcantly overestimate GFR in
advanced CKD while urea clearances underestimate it. Thus,
o n em e t h o dt oe s t i m a t et h eG F Ri st oa v e r a g eb o t ht h ec r e a -
tinine and urea clearances, although this will require further
study. There may be other potentially useful approaches to
determine cardiorenal prognosis for HF patients including
CGadjustedfor bodysurface area [8],cystatin-C[9–14],and
the Mayo eGFR formula [7].
3.IdentifyingPatientsat Riskfor
Worsening RenalFunctionBased on
ComorbidConditions
A careful history of coexistent medical conditions can
identify features that may increase the risk of subsequent
renal compromise. Forman et al. examined risk factors for
worsening renal function (WRF; deﬁned as rise in serum
creatinine of >0.3mg/dL) among 1,004 consecutive patients
admittedfora primary diagnosisofHF[15].The highest risk
of WRFwas associated with elevatedcreatinine atadmission.
However, the presence of diabetes (adjusted hazard ratio
[HR] 1.40) and a systolic blood pressure >160mmHg
(adjusted HR 1.37) were associated with a comparable risk
of WRF to that of a history of prior HF (adjusted HR 1.31).
A score derived from the regression model was useful in
stratifying patient risk of WRF as shown in Table 2.
OtherreportedriskfactorsforWRFthatcanbeidentiﬁed
at the time of admission for HF include
(i) rales/pulmonary edema [16, 17],
(ii) tachycardia [16],
(iii) female gender [16],
(iv) atrial ﬁbrillation [17],
(v) peripheral arterial disease [17].
4. Cardiorenal Syndromeand Medications
The medications used by a patient can also provide insight
into the stability of their cardiorenal axis. Furosemide is
the one of most commonly prescribed medications among
patients with HF, being used in over in 85% of outpatients
at the time of hospital discharge [18]. Furosemide doses
also frequently change among outpatients with HF [18].
In a study of 4,406 elderly patients discharged from an
HF hospitalization, the prescription of higher furosemide
doses (≥120mg/day) was more common among patients
with higher creatinine levels, preadmission furosemide use,
ischemic or valvular HF etiology, diabetes, atrial ﬁbrillation,
and COPD. Patients who were prescribed higher furosemideInternational Journal of Nephrology 3
Table 2: Risk score developed by Forman et al. to predict worsening renal function [15].
Risk factor Points
History of HF 1
Diabetes 1
Systolic blood pressure >160mmHg at admission 1
Creatinine levels ≥1.5 and <2.5mg/dL 2
Creatinine levels ≥2.5mg/dL 3
Score n % of patients with score % of Patients with worsening
renal function
Relative risk
0 123 12.3 9.8 Referent
1 257 25.6 18.7 1.9
2 251 25 20.3 2.1
3 155 15.4 30.3 3.1
4+ 218 21.7 52.8 5.4
doses were also more likely to exhibit hypotension, car-
diomegaly, hyponatremia, and lower haemoglobin levels.
After extensive adjustment for covariates, exposure to
higher furosemide dose was found to be predictive of death,
hospitalization and renal dysfunction over ﬁve years of
followup. Compared with the low-dose group (≤59mg/day
offurosemide),mediumdoseexposure(60–119mg/day)was
associated with increased mortality with an adjusted hazard
ratio of 1.96 (95% CI: 1.79–2.15) while high dose exposure
conferred an even greater mortality risk with a hazard ratio
of 3.00 (95% CI: 2.72–3.31; both P<. 001). There was a
comparable increase in the risk of death both in and out of
hospital, raising the possibility of an increased risk of both
pumpfailure andsuddendeath.These potentialmechanisms
of death were supported by the observation of a higher risk
of arrhythmias with increasing furosemide doses. Moreover,
there was a dose-dependent increase in hospitalization risk
that was strongest for HF events, suggesting that the adverse
outcomes are most speciﬁcally related to HF progression.
Similarly, the risk of renal dysfunction rose with increasing
furosemide exposure, such that medium dose and high dose
furosemide were associated with adjusted hazard ratios of
1.56 (95% CI: 1.38–1.76) and 2.16 (95% CI: 1.88–2.49)
compared to the low dose group [18]. These ﬁndings were
concordant with prior observations [19–22], suggesting that
furosemide dose may represent a valuable “pharmamarker”
of cardiorenal dysfunction, whose utility is enhanced by
its ubiquitous use and dynamic nature that may indicate
changes in HF control over time.
Treatment with angiotensin converting enzyme (ACE)
inhibitors or angiotensin-receptor blockers(ARBs)was asso-
ciated with improved prognosis in this study of furosemide
use. As a reﬂection of their heightened risk, the high-dose
furosemide group was less likely to be treated with ACE
inhibitors [18]. This mirrors the results of a retrospective
analysis of the Minnesota Heart Survey where ACE inhibitor
orARBuse was compared among 2,169patients hospitalized
with HF. There was progressively lower utilization of ACE
inhibitors with declining eGFR. However, the in-hospital use
ofACEinhibitorsorARBswasindependentlyassociatedwith
signiﬁcantly reduced 30-day mortality with an adjusted odds
ratio of 0.45 (95% CI: 0.28–0.59). Moreover, the discharge
prescription of an ACE inhibitor or ARB was associated
with a signiﬁcant reduction in adjusted 1-year mortality
with odds ratio of 0.72 (95% CI: 0.58–0.91) [23]. However,
there appears to be no mortality beneﬁt associated with ACE
inhibitor or ARB use among dialysis patients [23].
The most common concerns with ACE inhibitors and
ARBs include worsening renal function and/or hyper-
kalemia [24]. However, patient subgroups with perceived
contraindications to ACE inhibitors, including those with
renal dysfunction, may tolerate high-dose ACE inhibitors
well [25]. In a review of 12 randomized clinical trials of
ACE inhibitors in patients with renal dysfunction (serum
creatinine >1.4mg/dL), acute increases in serum creatinine
of up to 30% that stabilize within the ﬁrst two months of
ACE inhibitor therapy were strongly predictive of long-term
preservation of renal function. This prompted the authors
to recommend that ACE inhibitors should only be withheld
when the creatinine rise exceeds 30% above baseline within
the ﬁrst 2 months of initiation or if hyperkalemia develops
[26]. Moreover, an analysis from the Digitalis Investigation
Group trial showed that among patients with perceived
contraindications to ACE inhibitors (most commonly renal
insuﬃciency), use of ACE inhibitors was associated with
signiﬁcant survival beneﬁt at four-year followup [24].
5.(Micro)albuminuria
Albuminuria is a convergence point for several physiological
derangements common in HF and CKD such as volume
overload, hypertension, diabetes, and inﬂammation [27–
29]. The presence of proteinuria can serve as a marker of
structural kidney damage [30–32] that can precede overt
declines in renal function [33, 34]. Indeed, the presence
of dipstick proteinuria with nearly normal renal function
portends a higher risk of reaching end-stage renal disease
than stage 4 CKD in the absence of a positive dipstick test
[33, 34]. HF canalso lead to albuminuria evenin the absence
of overt kidney dysfunction [35]. Nevertheless, albuminuria
is more prevalent in HF patients with lower eGFR [35–37].
In the Valsartan in HF Trial, 5.6% of patients without CKD4 International Journal of Nephrology
(i.e., those with eGFR ≥60mL/min/1.73m2) had dipstick-
positive proteinuria compared to 10% of those with renal
dysfunction [35]. In the Gruppo Italiano per lo Studio della
Sopravvivenza nell’Infarto miocardico (GISSI-HF) trial,
impaired renal function (eGFR <60mL/min/1.73m2)w a s
present in 30.1% of patients with normal urinary albumin
excretion,45.0%ofthosewithmicroalbuminuria, and53.0%
ofthosewith albuminuria [37].Ithasbeenwell reported that
albuminuria isassociated with worse outcomesinapparently
h e a l t h ys u b j e c t sa sw e l la sp a t i e n t sw i t hc a r d i o v a s c u l a r
disease, diabetes, and CKD [33, 34, 38–44].
The urinary albumin to creatinine ratio may further
reﬁne risk in patients with HF. In an analysis of 2,310
patients from the CHARM program [36], those with an
elevated urinary albumin to creatinine ratio were older, had
worse renal function, and had higher diabetes prevalence.
They were also more likely to have been admitted for
HF, and a higher proportion had NYHA functional class
III or IV symptoms at randomization. The presence of
microalbuminuria independently predicted a higher rate of
adverse events, with hazard ratios for death of 1.62 (95% CI:
1.32–1.99) for microalbuminuria and 1.76 (95% CI: 1.32–
2.35) for macroalbuminuria compared to normoalbumin-
uria (both comparisons P<. 001) [36]. Similar observations
were reported in two subsequent studies [35, 37], one of
which demonstrated a progressive increase in the risk of
death throughout the range of UACR’s [37]. The proposed
mechanisms of the increased risk associated with proteinuria
are beyond the scope of this paper but have been reported
elsewhere [45].
6.Anemia
Anemia is a common condition in both HF and CKD. Its
estimated prevalence in patients with HF varies between
12–50% based on the cutoﬀsu s e d[ 46–51]. In a meta-
analysis of 153,180 HF patients from 34 studies, 37.2% were
anemic [49]. The prevalence of anemia appears to be similar
in patients with preserved and reduced left ventricular
systolic function [51–53]. It is also a well-established feature
of CKD, with anemia prevalence of 27% when eGFR is
≥60mL/min/1.73m2 to 75.5% in the presence of end-stage
renal disease [54]. While the etiology in advanced kidney
disease is believed to be mostly related to decreased erythro-
poietin production [55, 56], the anemia of HF is marked
by elevated erythropoietin levels, although the elevation is
often lower than expected for the degree of anemia [57, 58].
This may be a consequence of the heightened inﬂammatory
state that marks the HF syndrome [48, 57–59]. These factors
may explain the inconsistent responses to erythropoietin
stimulating agents in HF. Positive responses were observed
in early, small trials but were not consistently replicated
in larger trials with hard endpoints [60–63], including
the TREAT trial which showed a higher stroke risk with
darbepoetin alfa among patients with CKD and type 2
diabetes, approximately 1/3 of which had HF [61].
HF and CKD also share other elements that could
contribute to anemia such as iron deﬁciency, B12, folate and
other nutritional deﬁciencies, and hemodilution [55–57, 60,
64–67]. In addition, both disease states commonly require
the use of ACE inhibitors which decrease erythropoietin
levels [68] and impair the breakdown of hematopoeisis
inhibitors [58]. In a study of 59,772 adults with HF, the
prevalence of anemia was 37% in patients with eGFR
>60mL/min/1.73m2 compared to 82% in those with stage
5C K D[ 69]. Thus, HF and CKD may act synergistically to
increase the prevalence of anemia. Additionally, anemic HF
patients are more likely to be older with comorbid diabetes,
lower blood pressure, higher diuretic use, higher NYHA
functional class, reduced exercise capacity, worse quality of
life, and increased neurohormonal activity [46–48, 50, 51,
57, 60, 62, 65] .T h ep r e s e n c eo fa n e m i ai sa l s ol i n k e dt oa
greaterrisk ofdeathand hospitalization among patientswith
HF [48, 49, 53, 69]. In the meta-analysis by Groenveld et
al., 46.8% of anemic patients died compared with 29.5% of
non-anemic patients among 153,180 patients followed for a
minimum of6months [49].Anemiawasalsoassociated with
a hazard ratio of 1.43 for HF hospitalizations among 3,029
patients with NYHA class II to IV functional status and left
ventricular ejection fraction <35% [53].
The mortality risk associated with anemia appears to be
similar among patients with preserved or reduced ejection
fraction [52].However,themortalityrisk isnonlinearso that
it is disproportionately weighted towards patients with more
severe anemia [48, 53, 69]. Some reports have suggested
that the relationship is better approximated by a J-shaped
curve such that the risk of death may also be increased
in patients with supranormal hemoglobin levels [53, 69].
Among patients with CKD, anemia is also predictive of
development of end-stage renal disease [70], cardiovascular
events [71], and death [70, 71]. The contribution of anemia
to mortality risk is dependent on the degree of renal
dysfunction, likely reﬂecting the dominant eﬀect of renal
dysfunction onmortalityrisk in theCRS.Forexample, inthe
study by Go et al., the presence of hemoglobin <9.0g/dL was
associated with a hazard ratio for death of 5.91 in patients
with eGFR >60mL/min/1.73m2, while the hazard ratio was
1.99 in patients with eGFR <30mL/min/1.73m2 [69].
7.Biomarkers
The introduction of cardiac troponin assays revolutionized
the management of acute coronary syndromes (ACS) by
providing a powerful diagnostic and prognostic tool. With
widespread use came the recognition that cardiac troponins
can also serve as strong prognostic markers in HF and
CKD outside the ACS setting. Serum troponin levels are
elevated in 6–50% of patients with acute HF and have
been linked to an increased risk of death and cardiovascular
events among hospitalized and ambulatory patients with HF
throughout the spectrum of the disease [72–76]i nad o s e -
response relationship [74]. In the setting of CKD, troponin
measurements are frequently elevated in the absence of
overt cardiac pathology [77–84], partly due to decreased
renal clearance [85]. This CKD-associated elevation is more
prominent for troponin T relative to troponin I [77, 78, 83].
Troponin elevation in CKD reﬂects ongoing myocardial
damage andnecrosis andisstrongly associated withdiabetes,International Journal of Nephrology 5
left ventricular dilatation, and impaired left ventricular
systolicand diastolic function, withoutnecessarily indicating
the presence of severe coronary artery disease [86]. Eleva-
tions in troponin T have been more consistently linked to a
poor prognosis in patients with CKD [77–84, 87–89], while
studiesconductedusing troponinIhaveprovidedconﬂicting
results [77, 78, 83]. In a meta-analysis of 3,931 patients from
28 studies, elevated troponin T (>0.1ng/mL) was associated
with increased all-cause mortality with a relative risk of 2.64
(95%CI:2.17to3.20)inthesettingofend-stagerenaldisease
[78]. An important caveat is that blood measurements of
troponin should be obtained just before dialysis [90].
B-type(brain)natriureticpeptide(BNP)andN-terminal
pro-BNP (NT-pro-BNP) have also emerged as valuable
markers of HF severity [91] .S i n c et h e yh a v ed i ﬀerent
clearance kinetics, their levels are not interchangeable,
although they often correlate with each other. In particular,
the clearance of NT-proBNP appears to be more aﬀected
by renal dysfunction than that of BNP [92]. However, both
natriuretic peptides are elevated in patients with advanced
CKD, suggesting that the elevation is multifactorial and not
simply a result of decreased clearance [93–96]. Elevated
levels of either natriuretic peptide are predictive of adverse
outcomes among patients with HF. In a meta-analysis of 19
studies, each 100pg/mL increase in BNP was associated with
a 35% increase in the relative risk of death [97]. There is less
data on the prognostic value of NT-proBNP in unselected
patientswithHF butitappears to confer similar information
to BNP [98]. Natriuretic peptides are also predictive of
outcomes in patients with preserved systolic function, where
the severity of diastolic dysfunction has been found to
correlate with increased levels of both BNP and NT-proBNP
[99, 100]. The negative prognosis associated with natriuretic
peptide elevation in CKD has been demonstrated in several
studies [92].
The prognostic eﬀects of these biomarkers are main-
tained in those with combined HF and renal disease. Their
levels are still well correlated with left ventricular wall stress
[101] and prognosis, although a higher NT-proBNP cutoﬀ
valueisneededtoseparatepatientswithpoorandintermedi-
ate prognosis. Bruch et al. compared the prognostic value of
NT-proBNP in 183 ambulatory HF patients with CKD and
153 with eGFR >60mL/min/1.73m2 and concluded that a
cutoﬀvalueof1,474pg/mLbestseparated patientswith poor
and intermediate prognosis. Among patients with HF and
CKD, cardiac event-free survival was 48% in patients above
this cut-oﬀ compared with 93% in patients below it [102].
Anwarrudin et al. performed a similar analysis in patients
presenting to the emergency department with HF, reaching
the conclusion that NT-proBNP elevation was the strongest
overall independent risk factor for 60-day mortality among
those with eGFR <60mL/min/1.73m2 with hazard ratio of
1.61 (95% CI: 1.14–2.26). NT-proBNP also independently
predicted HF hospitalization with a hazard ratio of 1.26
[103].
The use of natriuretic peptides as prognostic variables
requiresattention toa few caveats.Firstly, natriuretic peptide
levels are lower in obese patients, although they do maintain
good diagnostic and prognostic value when used with
appropriately lowered cut-oﬀs[ 104]. Natriuretic peptides
are also less useful in evaluating HF due to causes other
than left ventricular dysfunction such as mitral stenosis or
pericardial disease [91, 105, 106]. Ideally, natriuretic peptide
levels should be used as a continuous variable that takes into
account the patient’s baseline levels if available [91].
The use of biomarkers in this setting will undoubtedly
continue to grow. Neutrophil gelatinase-associated lipocalin
(NGAL) is an early marker of acute kidney injury with
improved kinetics in comparison to traditional markers of
renal clearance [107, 108], which may independently predict
prognosis in CRS [109–113]. Similarly, Cystatin C is a small
serine protease inhibitor which is also being touted as a
more accurate and earlier marker of renal dysfunction [10–
14] and has already been shown to be a potent predictor
of cardiovascular events and all-cause mortality in patients
with and without overt cardiac or renal dysfunction [114–
120]. The increasing utility of such biomarkers has sparked
growing interest in “multimarker” approaches to assess
disease severityand prognosis in thesetting ofthe CRS[121–
127]. However, it should be emphasized that biomarkers
should be used as an adjunct to rather than a replacement
for a full clinical assessment [128].
8.PulmonaryHypertension
Pulmonary hypertension is a well-recognized consequence
of HF, which constitutes Group 2 within the World Health
Organization’s classiﬁcation of pulmonary hypertension
[129]. Patients with CKD often have cardiac disease and
pulmonary comorbidities such as sleep apnea that can
lead to the development of pulmonary hypertension via
increased left atrial pressure or chronic hypoxia in the
absence ofpulmonary arterial pathology[130–133].The dis-
proportionate prevalence of pulmonary hypertension in the
absence of these causes within the CKD population is much
less appreciated. In one study of patients with end-stage
renal disease who did not have overt cardiac dysfunction
or pulmonary disease, Doppler 2D echocardiography was
used to estimate right ventricular systolic pressure 1-hour
postdialysis, while at their dry weight. Of the study cohort,
39.7% had an estimated right ventricular systolic pressure
>35mmHg, while 13.8% had values >45mmHg [130]. This
high prevalence of pulmonary hypertension was replicated
in two other studies from diﬀerent continents [134, 135]. It
is controversial whether pulmonary hypertension relates to
the presence of end-stage renal disease itself or whether it is a
consequence of dialysis, particularly via an arteriovenous ﬁs-
tula [130]. However, with reported prevalence of pulmonary
hypertension as high as 39.1% in patients awaiting dialysis,
and the improvement (and possible normalization) of right
ventricular pressures among patients with end-stage renal
disease afterrenal transplantation, evidenceofan association
is strengthened [130, 136].
The development of pulmonary hypertension in the
presence of advanced CKD may be a harbinger of poor
outcomes. In a study of 127 hemodialysis patients, 17
patients had pulmonary hypertension at dialysis outset, and
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initiation. After multivariate adjustment, the presence of
pulmonaryhypertensionpriortodialysiswasassociated with
ahazard ratioof3.6fordeath(95%CI:1.8–7.0)compared to
patients without the condition at baseline. The development
of new pulmonary hypertension after initiation of dialysis
was associated with an adjusted hazard ratio for death of
2.1 (95% CI: 1.1–4.3) [133]. It remains unclear why the
presence of pulmonary hypertension increases risk of death
so prominently in the end-stage renal disease population
that already has a high rate of events. The presence of
pulmonary hypertension may be associated with higher risk
of adverse outcomes because it may reﬂect (a) advanced
cardiac or respiratory disease, (b) greater severity of kid-
ney disease-associated endothelial dysfunction secondary to
nitric oxide and endothelin-1 derangements [136–139], (c)
greater derangement of calcium metabolism with greater
subsequent vascular calciﬁcation [135], (d) a state of high
cardiac output in patients with arteriovenous ﬁstulas [130,
135,136,140,141]which caninducehigh outputHF,and(e)
undiagnoseddiastolicdysfunction,chronicvolumeoverload,
chronic hypoxia, or recurrent pulmonary embolic events
[134, 135, 142].
9.Conclusion
The development of the CRS is linked to a marked increase
in the rates of death and morbidity compared to patients
with either HF or CKD in isolation. However, there are
multiple widely available noninvasive factors that can help
the clinician estimate prognosis more accurately within
this large and heterogeneous patient group. An assessment
of left ventricular ejection fraction, renal function, and
functional status remain paramount. The identiﬁcation of
co-existent diagnoses may indicate a high risk of worsening
renal failure during HF hospitalization. The use of high
furosemide doses or nonuse of ACE inhibitors or ARBs
may identify patients with a tenuous cardiorenal axis or
possibly suboptimal medical management. The presence of
concomitant microalbuminuria or anemia may also provide
clues to greater severity of cardiorenal compromise. The use
of biomarkers such as BNP, troponin, NGAL, and cystatin-
C can provide additional information in monitoring this
patient group. Finally, surveillance for pulmonary hyperten-
sion in patients with end-stage renal disease might allow for
further reﬁnement of prognosis in this patient group with its
exceedingly high risk of death or morbidity.
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